Aesica has entered into a collaboration with Britest under whichmembers will share knowledge and risk to establish innovative solutions to manufacturing challenges. Britest has engaged 22 global chemical and pharmaceutical organizations and several academic organizations. The partnerships will utilize and further develop Britest’s tools and methodologies to support whole process understanding. Aesica will use these tools to identify new approaches and technologies to improve API manufacturing processes. The Aesica Innovation Board (AIB) aims to commercialize any new technologies.
Dr. Barrie Rhodes, Aesica director of technology development, said, “At Aesica we aspire to develop and implement new technologies and improve processes to support business growth. Following the successful demonstration of the Britest approach on a key Active Pharmaceutical Ingredient process at our Cramlington site, we are now looking forward to engaging fully in the Britest collaboration and implementing the Britest approach across a range of processes.”
Sue Fleet, Britest chief executive officer, said, “I am delighted to welcome Aesica Pharmaceuticals as our latest company member. With a clear focus on innovation and collaboration, we look forward to supporting Barrie and his colleagues at Aesica in driving innovative thinking and deriving full value from their membership of Britest.”